<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21009">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02833389</url>
  </required_header>
  <id_info>
    <org_study_id>GX29915</org_study_id>
    <secondary_id>2015-003283-36</secondary_id>
    <nct_id>NCT02833389</nct_id>
  </id_info>
  <brief_title>The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A in Participants With Neuropathic Non-Healing Diabetic Foot Ulcers</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This trial will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of
      repeat dosing of UTTR1147A in patients with neuropathic diabetic foot ulcers that do not
      respond adequately to standard wound care. Patients across multiple sites will be assigned
      to one of the 4 cohorts (Cohort A, B, C and D) based on the eligibility criteria and
      randomized to receive subcutaneous (SC) injections of either UTTR1147A or placebo over 12
      weeks, in addition to standard wound care.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nature, frequency, severity, and timing of adverse events</measure>
    <time_frame>Baseline up to Day 141</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of UTTR1147A</measure>
    <time_frame>Pre-dose on Days 1, 22, 43, and 64, on Days 4, 8, 71, 85, and 99, early termination (up to Day 141)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in index ulcer surface area at Weeks 6 and 12</measure>
    <time_frame>Baseline, 6 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with anti-therapeutic (anti-UTTR1147A) antibodies (ATAs)</measure>
    <time_frame>Day 1, 22, 64, 85, 99, early termination visit (up to Day 141)</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Neuropathic Diabetic Foot Ulcers</condition>
  <arm_group>
    <arm_group_label>Cohort A - UTTR1147A, 1-5 cm^2, No infection - Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with 1-5 cm^2 index ulcer area at screening and no infection in index ulcer will receive UTTR1147A SC at Dose 1 level for 12 weeks (a total of 4 doses).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B - UTTR1147A, 1-5 cm^2, No infection - Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with 1-5 cm^2 index ulcer area at screening and no infection in index ulcer will receive UTTR1147A SC at Dose level 2 for 12 weeks (a total of 4 doses).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C - UTTR1147A, 1-5 cm^2, mild infection - Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with 1-5 cm^2 index ulcer area at screening and mild infection in index ulcer will receive UTTR1147A SC at Dose level 2 for 12 weeks (a total of 4 doses).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D - UTTR1147A, 2-5 cm^2, mild infection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with 2-5 cm^2 index ulcer area at screening and mild infection in index ulcer will receive UTTR1147A SC at Dose level 2 for 12 weeks (a total of 4 doses).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive UTTR1147A matching placebo SC in each cohort for 12 weeks (a total of 4 doses).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>UTTR1147A matching placebo will be administered SC.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UTTR1147A</intervention_name>
    <description>UTTR1147A will be administered SC.</description>
    <arm_group_label>Cohort A - UTTR1147A, 1-5 cm^2, No infection - Dose 1</arm_group_label>
    <arm_group_label>Cohort B - UTTR1147A, 1-5 cm^2, No infection - Dose 2</arm_group_label>
    <arm_group_label>Cohort C - UTTR1147A, 1-5 cm^2, mild infection - Dose 2</arm_group_label>
    <arm_group_label>Cohort D - UTTR1147A, 2-5 cm^2, mild infection</arm_group_label>
    <other_name>RO7021610</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a diagnosis of Type 1 or Type 2 diabetes and confirmed peripheral neuropathy

          -  Have adequate circulation to the foot

          -  Have an ulcer area at screening up to 5 centimeters square (cm^2)

          -  Up to date on all age-appropriate cancer screenings per local standards

        Exclusion Criteria:

          -  Have current evidence of osteomyelitis, cellulitis, or evidence of systemic infection

          -  Have gangrene present on any part of the affected foot

          -  Known peripheral arterial disease (PAD) requiring revascularization

          -  Have a glycated hemoglobin A1C (HbA1c) level of greater than (&gt;) 12 percent (%)
             assessed at screening

          -  Are receiving oral or parenteral corticosteroids, immunosuppressive, or cytotoxic
             agents

          -  Have active malignancy or any history of a malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: GX29915 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global.rochegenentechtrials@roche.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Firenze</city>
        <state>Toscana</state>
        <zip>50141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Pisa</city>
        <state>Toscana</state>
        <zip>56100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Donostia</city>
        <state>Guipuzcoa</state>
        <zip>20080</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Alcorcon</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Barakaldo</city>
        <state>Vizcaya</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Albacete</city>
        <zip>2006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Bradford</city>
        <zip>BD9 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Derby</city>
        <zip>DE22 3DT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ipswich</city>
        <zip>IP4 5PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <zip>NR4 7TJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Sheffield</city>
        <zip>S5 7AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 1, 2016</lastchanged_date>
  <firstreceived_date>July 12, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
